Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Ishares Msci Italy ETF (EWI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Ishares Msci Italy ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Ishares Msci Italy ETF trades at $63.12. Which is the better fit depends on your goals.
| BIO | EWI | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $356.25 | $63.35 |
52-Week Low | $241.71 | $50.31 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.
Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.
EWI trades at $63.165, showing minimal daily movement with a slight decline of 0.01%. The technical outlook is bullish based on moving averages, though oscillators signal neutrality with RSI readings above 80 indicating potential overbought conditions. Recent news highlights Italy's market strength with EWI hitting a 52-week high in June 2026, driven by improving industrial data and recovery narrative. A dividend of $1.17 is scheduled for June 2026, providing income appeal.
The stock benefits from positive European market sentiment and Italy's economic recovery, but faces risks from ECB rate policy and energy price volatility. Technical indicators suggest near-term consolidation may be needed given overbought signals. Long-term prospects appear favorable if Italy's economic momentum continues, though investors should monitor ECB decisions and energy market developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →
